Literature DB >> 29046310

Protein Structure Facilitates High-Resolution Immunological Mapping.

Madison Zuverink1, Joseph T Barbieri2.   

Abstract

Select agents (SA) pose unique challenges for licensing vaccines and therapies. In the case of toxin-mediated diseases, HHS assigns guidelines for SA use, oversees vaccine and therapy development, and approves animal models and approaches to identify mechanisms for toxin neutralization. In this commentary, we discuss next-generation vaccines and therapies against ricin toxin and botulinum toxin, which are regulated SA toxins that utilize structure-based approaches for countermeasures to guide rapid response to future biothreats.
Copyright © 2017 American Society for Microbiology.

Entities:  

Keywords:  RTA; RVEc; RiVax; antibodies; botulinum toxin; mass spectrometry; ricin

Mesh:

Substances:

Year:  2017        PMID: 29046310      PMCID: PMC5717179          DOI: 10.1128/CVI.00275-17

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  56 in total

1.  Subunit vaccine efficacy against Botulinum neurotoxin subtypes.

Authors:  James S Henkel; William H Tepp; Amanda Przedpelski; Robert B Fritz; Eric A Johnson; Joseph T Barbieri
Journal:  Vaccine       Date:  2011-08-10       Impact factor: 3.641

2.  Bivalent recombinant vaccine for botulinum neurotoxin types A and B based on a polypeptide comprising their effector and translocation domains that is protective against the predominant A and B subtypes.

Authors:  Clifford Shone; Heidi Agostini; Joanna Clancy; Mili Gu; Huei-Hsiung Yang; Yanfang Chu; Virginia Johnson; Makie Taal; Joanna McGlashan; John Brehm; Xiaomi Tong
Journal:  Infect Immun       Date:  2009-04-27       Impact factor: 3.441

3.  Crystal structures of ricin toxin's enzymatic subunit (RTA) in complex with neutralizing and non-neutralizing single-chain antibodies.

Authors:  Michael J Rudolph; David J Vance; Jonah Cheung; Matthew C Franklin; Fiana Burshteyn; Michael S Cassidy; Ebony N Gary; Cristina Herrera; Charles B Shoemaker; Nicholas J Mantis
Journal:  J Mol Biol       Date:  2014-06-04       Impact factor: 5.469

4.  Mapping of the antibody-binding regions on botulinum neurotoxin H-chain domain 855-1296 with antitoxin antibodies from three host species.

Authors:  M Z Atassi; B Z Dolimbek; M Hayakari; J L Middlebrook; B Whitney; M Oshima
Journal:  J Protein Chem       Date:  1996-10

Review 5.  Assembly and function of the botulinum neurotoxin progenitor complex.

Authors:  Shenyan Gu; Rongsheng Jin
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

6.  An intact interchain disulfide bond is required for the neurotoxicity of tetanus toxin.

Authors:  G Schiavo; E Papini; G Genna; C Montecucco
Journal:  Infect Immun       Date:  1990-12       Impact factor: 3.441

7.  Enhancing the protective immune response against botulism.

Authors:  Amanda Przedpelski; William H Tepp; Abby R Kroken; Zhuji Fu; Jung-Ja P Kim; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2013-05-13       Impact factor: 3.441

8.  Subunit vaccine against the seven serotypes of botulism.

Authors:  Michael R Baldwin; William H Tepp; Amanda Przedpelski; Christina L Pier; Marite Bradshaw; Eric A Johnson; Joseph T Barbieri
Journal:  Infect Immun       Date:  2007-12-10       Impact factor: 3.441

9.  Localization of non-linear neutralizing B cell epitopes on ricin toxin's enzymatic subunit (RTA).

Authors:  Joanne M O'Hara; Jane C Kasten-Jolly; Claire E Reynolds; Nicholas J Mantis
Journal:  Immunol Lett       Date:  2013-11-21       Impact factor: 3.685

10.  Elimination of Maternal and Neonatal Tetanus in India: A Triumph Tale.

Authors:  Kalaivani Annadurai; Raja Danasekaran; Geetha Mani
Journal:  Int J Prev Med       Date:  2017-03-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.